X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE BIOCON LTD SUVEN LIFE/
BIOCON LTD
 
P/E (TTM) x 19.2 82.9 23.1% View Chart
P/BV x 3.6 7.8 45.6% View Chart
Dividend Yield % 1.1 0.2 663.1%  

Financials

 SUVEN LIFE   BIOCON LTD
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
BIOCON LTD
Mar-17
SUVEN LIFE/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs3391,162 29.1%   
Low Rs144483 29.9%   
Sales per share (Unadj.) Rs39.2194.6 20.2%  
Earnings per share (Unadj.) Rs7.534.4 21.7%  
Cash flow per share (Unadj.) Rs8.848.3 18.2%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.80.1 681.1%  
Book value per share (Unadj.) Rs49.0241.9 20.3%  
Shares outstanding (eoy) m127.28200.00 63.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.24.2 145.6%   
Avg P/E ratio x32.423.9 135.4%  
P/CF ratio (eoy) x27.517.0 161.5%  
Price / Book Value ratio x4.93.4 145.0%  
Dividend payout %26.82.9 922.2%   
Avg Mkt Cap Rs m30,732164,440 18.7%   
No. of employees `0001.09.2 10.3%   
Total wages/salary Rs m4167,470 5.6%   
Avg. sales/employee Rs Th5,236.14,213.9 124.3%   
Avg. wages/employee Rs Th436.5809.0 54.0%   
Avg. net profit/employee Rs Th995.5745.2 133.6%   
INCOME DATA
Net Sales Rs m4,99538,911 12.8%  
Other income Rs m1941,571 12.3%   
Total revenues Rs m5,18940,482 12.8%   
Gross profit Rs m1,2339,795 12.6%  
Depreciation Rs m1672,772 6.0%   
Interest Rs m54260 20.8%   
Profit before tax Rs m1,2058,334 14.5%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2551,616 15.8%   
Profit after tax Rs m9506,881 13.8%  
Gross profit margin %24.725.2 98.0%  
Effective tax rate %21.219.4 109.2%   
Net profit margin %19.017.7 107.5%  
BALANCE SHEET DATA
Current assets Rs m4,98640,477 12.3%   
Current liabilities Rs m1,04216,783 6.2%   
Net working cap to sales %79.060.9 129.7%  
Current ratio x4.82.4 198.4%  
Inventory Days Days6160 102.3%  
Debtors Days Days3983 47.2%  
Net fixed assets Rs m3,12645,073 6.9%   
Share capital Rs m1271,000 12.7%   
"Free" reserves Rs m3,71747,377 7.8%   
Net worth Rs m6,23648,377 12.9%   
Long term debt Rs m43221,082 2.1%   
Total assets Rs m8,07993,942 8.6%  
Interest coverage x23.233.1 70.3%   
Debt to equity ratio x0.10.4 15.9%  
Sales to assets ratio x0.60.4 149.3%   
Return on assets %12.47.6 163.5%  
Return on equity %15.214.2 107.1%  
Return on capital %18.912.6 149.7%  
Exports to sales %87.50-   
Imports to sales %12.20-   
Exports (fob) Rs m4,371NA-   
Imports (cif) Rs m611NA-   
Fx inflow Rs m4,66612,988 35.9%   
Fx outflow Rs m9427,899 11.9%   
Net fx Rs m3,7245,089 73.2%   
CASH FLOW
From Operations Rs m9226,400 14.4%  
From Investments Rs m-619-4,985 12.4%  
From Financial Activity Rs m-698-1,775 39.3%  
Net Cashflow Rs m-396-473 83.7%  

Share Holding

Indian Promoters % 63.4 40.4 156.9%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 0.0 8.4 -  
FIIs % 0.0 10.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 19.9 183.4%  
Shareholders   37,287 109,995 33.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare SUVEN LIFE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 23, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE 8-QTR ANALYSIS

COMPARE SUVEN LIFE WITH

MARKET STATS